posted on 2017-05-16, 08:58authored byAdam K. A. Wright, Cathryn Weston, Batika M. J. Rana, Christopher E. Brightling, David J. Cousins
Group 2 innate lymphoid cells (ILC2s) are upstream regulators of IL-5-dependent
eosinophil function in asthma. We’ve shown that ILC2s do not express the IL-5R and thus IL-5R-
dependent therapeutic interventions (e.g. Benralizumab) are unlikely to be mediated directly on
ILC2s.
Funding
This work was part funded by (for CEB) Airway Disease Predicting Outcomes
through Patient Specific Computational Modelling (AirPROM) project (funded through FP7 EU
grant), Wellcome Senior Fellowship, (for DJC) Medical Research Council (MRC) and Asthma UK
(Centre Grant: G1000758), from the NIHR Biomedical Research Centre based at Guy's and St
Thomas' NHS Foundation Trust and King's College London, an equipment grant from the Midlands
Asthma and Allergy Research Association (MAARA) and (for CEB and DJC) the National Institute
for Health Research (NIHR) Leicester Respiratory Biomedical Unit. BMJR was funded by an MRC
and Asthma UK PhD studentship. This paper presents independent research funded by the NIHR.
History
Citation
Journal of Allergy and Clinical Immunology, 2017
Author affiliation
/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGY/School of Medicine/Department of Infection, Immunity and Inflammation
Version
VoR (Version of Record)
Published in
Journal of Allergy and Clinical Immunology
Publisher
Elsevier for American Academy of Allergy, Asthma and Immunology